ViiV Healthcare
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, ViiV Healthcare sits in the top decile of US sponsors by registered trial count (#165 of 15,742 sponsors by registered trial count).
ViiV Healthcare: 182 sponsored US clinical trials, 7 recruiting.
ViiV Healthcare sponsors 182 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 147 completed. 47 of these trials are in Phase 3-4 (later-stage) and 132 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 36 trials.
Top-decile sponsor footprint
ViiV Healthcare ranks in the top decile of sponsors by registered trial count (#165 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
147 of 163 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
182 total, page 4 of 4
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
NCT00950859
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
NCT00951015
Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
NCT00920426
GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir
NCT00867152
A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients
NCT00827112
Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults
NCT00708110
Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.
NCT00812318
Prospective Observational Epidemiologic Study of Maraviroc's Safety
NCT00665561
A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects
NCT00666705
GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study
NCT00631592
Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay
NCT00496782
Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection
NCT00440947
Expanded Access Program for Maraviroc At Multiple Centers
NCT00426660
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
NCT00242879
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects
NCT00197145
GW873140 In Combination With Combivir In HIV Infected Subjects
NCT00104429
Fosamprenavir Versus Other Protease Inhibitors
NCT00094523
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
NCT00098722
GW873140 In Combination With Kaletra In HIV Infected Subjects
NCT00102778
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
NCT00098306
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
NCT00098293
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects
NCT00098748
GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults
NCT00257621
48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
NCT00089583
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
NCT00071760
Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
NCT00634959
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
NCT00242840
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
NCT00046176
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects
NCT00044577
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
NCT00040664
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
NCT00038506
A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects
NCT00296504
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 98 |
| Phase 2 | 34 |
| Phase 3 | 39 |
| Phase 4 | 8 |
What is open in the ViiV Healthcare pipeline
7 recruiting of 182 indexed (4% open); 147 completed (81%).
Phase mix: 47 late (III/IV) vs 132 early (I/II) (early-phase heavy).
Top condition: HIV Infections (36 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ViiV Healthcare: open-pipeline peers nationwide
Peers matched on 182 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
ViiV Healthcare sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 182 trials (± recruiting share)
- Fox Chase Cancer Center · 183 trials · 16% recruiting
- Abbott · 181 trials · 0% recruiting
- Children's Mercy Hospital Kansas City · 184 trials · 11% recruiting
- Baylor Research Institute · 180 trials · 17% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Aldeyra Therapeutics · 4% recruiting · 26 trials
- DexCom · 4% recruiting · 26 trials
- MaineHealth · 4% recruiting · 26 trials
- Medtronic Spinal and Biologics · 4% recruiting · 26 trials
Related
What to do with this ViiV Healthcare page
182 registered trials is a research-attention snapshot, not an endorsement of ViiV Healthcare or any single study.
- 7 of ViiV Healthcare's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition ViiV Healthcare studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. ViiV Healthcare pipeline card: 182 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.